Source:http://linkedlifedata.com/resource/pubmed/id/10397263
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
13
|
| pubmed:dateCreated |
1999-7-28
|
| pubmed:abstractText |
Cytogenetically, synovial sarcoma (SS) is characterized by the translocation t(X;18)(p11.2;q11.2), resulting in a fusion between the SYT gene on chromosome 18 and SSX1 or SSX2 on the X chromosome and the formation of new chimeric genes, SYT-SSX1 or SYT-SSX2. We examined the potential clinical relevance of SYT-SSX1 and SYT-SSX2 fusion transcripts together with tumor proliferation. In a series of 33 patients with primary SS, the type of fusion transcript was assessed by reverse transcription-PCR and sequence analysis. The proliferation rate was analyzed using anti-Ki-67 antibodies. One case carrying an atypical transcript with a 57-bp insert was excluded, leaving 13 SYT-SSX1 and 19 SYT-SSX2 cases for analysis. The hazard ratio (with respect to metastasis-free survival for patients with SYT-SSX1 versus patients with SYT-SSX2 fusion transcripts was 7.4 (95% confidence interval, 1.5-36; log-rank P = 0.004). There was also an association with reduced overall survival for patients with SYT-SSX1 compared to patients with SYT-SSX2 (hazard ratio, 8.5; 95% confidence interval, 1.0-73; log-rank P = 0.02). The 5-year metastasis-free survival for patients with SYT-SSX1 was 42% versus 89% for patients with SYT-SSX2. There was a significant association between SYT-SSX1 and a high tumor proliferation rate (P = 0.02). We conclude that the findings suggest that the type of SYT-SSX fusion transcript determines the proliferation rate and is an important predictor of clinical outcome in patients with SS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0008-5472
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
59
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3180-4
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:10397263-Adolescent,
pubmed-meshheading:10397263-Adult,
pubmed-meshheading:10397263-Aged,
pubmed-meshheading:10397263-Base Sequence,
pubmed-meshheading:10397263-Cell Division,
pubmed-meshheading:10397263-Child,
pubmed-meshheading:10397263-Chromosome Mapping,
pubmed-meshheading:10397263-Chromosomes, Human, Pair 18,
pubmed-meshheading:10397263-Disease-Free Survival,
pubmed-meshheading:10397263-Female,
pubmed-meshheading:10397263-Genetic Variation,
pubmed-meshheading:10397263-Humans,
pubmed-meshheading:10397263-Male,
pubmed-meshheading:10397263-Middle Aged,
pubmed-meshheading:10397263-Molecular Sequence Data,
pubmed-meshheading:10397263-Oncogene Proteins, Fusion,
pubmed-meshheading:10397263-Predictive Value of Tests,
pubmed-meshheading:10397263-Sarcoma, Synovial,
pubmed-meshheading:10397263-Sequence Alignment,
pubmed-meshheading:10397263-Survival Rate,
pubmed-meshheading:10397263-Translocation, Genetic,
pubmed-meshheading:10397263-Treatment Outcome,
pubmed-meshheading:10397263-Tumor Markers, Biological,
pubmed-meshheading:10397263-X Chromosome
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome.
|
| pubmed:affiliation |
Cellular and Molecular Tumor Pathology, CCK, Karolinska Hospital, Stockholm, Sweden.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|